Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $125.00

Monopar Therapeutics (NASDAQ:MNPR) had its price objective hoisted by HC Wainwright from $105.00 to $125.00 in a research note issued to investors on Wednesday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at ($1.35) EPS, FY2028 earnings at $0.91 EPS, FY2029 earnings at $2.41 EPS and FY2030 earnings at $6.61 EPS.

A number of other analysts have also commented on MNPR. Chardan Capital reiterated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday, March 30th. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Finally, UBS Group set a $105.00 price target on shares of Monopar Therapeutics in a research report on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and an average price target of $112.08.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $109.87 on Wednesday. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $116.64. The company has a market cap of $736.02 million, a P/E ratio of -57.83 and a beta of 1.46. The stock’s fifty day moving average price is $80.50 and its 200-day moving average price is $66.67.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.41. On average, sell-side analysts anticipate that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP bought a new stake in Monopar Therapeutics in the third quarter worth $18,904,000. Siren L.L.C. bought a new position in Monopar Therapeutics during the fourth quarter valued at $13,863,000. Deerfield Management Company L.P. purchased a new position in shares of Monopar Therapeutics in the 3rd quarter worth $13,048,000. RA Capital Management L.P. grew its stake in shares of Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth about $12,496,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.